Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: teriparatide
DRUG: Placebo
DRUG: BA058 20 µg
DRUG: BA058 40 µg
DRUG: BA058 80 µg

Sponsor

Radius Health, Inc.